Skip to content
2000
  • ISSN: 1568-0118
  • E-ISSN: 1875-5968

Abstract

Despite a number of advances in the past decades the medicinal cancer therapy is hampered by problems of severe unwanted side effects and the development of resistances. Many established anti-cancer drugs are directed toward targets that are not specific for cancer but are essential biochemical molecules in living cells. Because cancer cells do not only carry one but multiple genetic alterations which are more characteristic for the individual patient than for the tumor entity, an individualized medicinal approach could improve the success of a tumor therapy. A prerequisite for personalized tumor therapies is an upgrade of the array of anticancer drugs directed to different molecular targets. Therefore, a systematic search for anticancer drug targets should constitute a research priority. The database of fingerprints of new chemical entities generated in the National Cancer Institute's Anticancer Drug Screening is a rich source of novel targets which might be uncovered by the interdisciplinary application of methods from bioinformatics, biochemistry, chemistry, tumor biology and related sciences.

Loading

Article metrics loading...

/content/journals/cmcaca/10.2174/1568011043352858
2004-09-01
2025-09-08
Loading full text...

Full text loading...

/content/journals/cmcaca/10.2174/1568011043352858
Loading

  • Article Type:
    Review Article
Keyword(s): affinity approach; compare; darpones; drug target; national cancer institute
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test